



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/575,480	05/19/2000	Gregory A Kopia	CRD-850	1106
7590 02/24/2006				
Audley A Ciamporcero Jr One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003				
			EXAMINER NGUYEN, CAMTU TRAN	
			ART UNIT 3743	PAPER NUMBER
DATE MAILED: 02/24/2006				

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

MAILED

FEB 24 2006

Group 3700

**BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES**

Application Number: 09/575,480

Filing Date: May 19, 2000

Appellant(s): KOPIA ET AL.

Paul Coletti
For Appellant

EXAMINER'S ANSWER

This is in response to the appeal brief filed December 1, 2005 appealing from the Office action mailed June 2, 2004.

(1) Real Party in Interest

A statement identifying by name the real party in interest is contained in the brief.

(2) Related Appeals and Interferences

The following are the related appeals, interferences, and judicial proceedings known to the examiner which may be related to, directly affect or be directly affected by or have a bearing on the decision in the pending appeal is contained in the brief.

(3) Status of Claims

The statement of the status of claims contained in the brief is correct.

(4) Status of Amendments After Final

The appellant's statement of the status of amendments after final rejection contained in the brief is correct.

(5) Summary of Claimed Subject Matter

The summary of claimed subject matter contained in the brief is correct.

(6) Grounds of Rejection to be Reviewed on Appeal

The appellant's statement of the grounds of rejection to be reviewed on appeal is correct.

(7) Response to Argument

Applicant's arguments filed on December 1, 2005 have been carefully considered but they are not persuasive.

Regarding the drug Taxol as a rapamycin "analogue", applicant's specification support the antiproliferative agent includes taxol and rapamycin. In particular, on page 5 lines 14 applicant discloses "Antiproliferative action on SMC *in vitro* has been demonstrated for many of these agents, including heparin and heparin conjugates, taxol, tranilast, colchicines, ACE inhibitors, fusion toxins, antisense oligonucleotides, rapamycin, and ionizing radiation". At another occasion on page 8 lines 25-27 where the specification recite "a tyrosine kinase inhibitor, such as tyrphostin, might be combined with an antiproliferative agent such as taxol, vincristine, or rapamycin" and again later in the same paragraph, it recites "alternatively, an antiproliferative agent such as taxol, vincristine, or rapamycin". In addition, applicant originally filed claims 5 and 7, now cancelled, wherein rapamycin and taxol were paired in a Markush grouping and the agents, then, cited as "analogue". Claims 5 and 7, as originally filed, were properly recited and supported by the specification.

For the reasons and evidences above and in light of the specification, there is ample of support that taxol an equivalent of a rapamycin analogue and is indeed a rapamycin analogue.

For the above reasons, it is believed that the rejections should be sustained.

Respectfully submitted,

Camtu Nguyen


Application/Control Number: 09/575,480

Page 4

Art Unit: 3743

Conferees:

Henry Bennett


Henry Bennett
Supervisory Patent Examiner
Group 3700

~~Kim M. Lewis~~

KIM M. LEWIS
PRIMARY EXAMINER